Clinical Trial Update: Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for nebulized heparin in COVID-19–related lung injury has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Injury
• Respiratory Distress Syndrome

Drugs mentioned

• Nebulized Heparin (unfractionated heparin)

Snippet

Sponsor: Frederick Health | Conditions: Covid-19, ARDS, Human | Phase 4 | Status: TERMINATED